Rates Of Repeat Egd In Non-Diabetic Adults With Glucagon-Like-Peptide- 1 Receptor Agonist Prescription: A Retrospective Matched Cohort Study

Abbinaya Elangovan,Pearl Aggarwal,David C. Kaelber,Raj Shah
DOI: https://doi.org/10.1016/j.gie.2024.10.004
IF: 10.396
2024-10-12
Gastrointestinal Endoscopy
Abstract:Background and aims Data on endoscopic outcomes in adults without diabetes who are taking glucagon like peptide receptor agonist (GLP-1 RA) is limited so we aimed to compare repeat esophagogastroduodenoscopy (EGD) in this population to those without GLP-1 using retrospective matched case-control study. Methods Using TriNetX (Cambridge, MA), adults with BMI of ≥27 kg/m2 without diabetes who underwent diagnostic EGD were analyzed. Study group included individuals with ≥3 GLP-1 prescriptions and EGD ≥30 days after initial GLP-1 prescription. Control group was never prescribed GLP-1 RAs but had EGD after prescription of other weight loss medications. Outcomes were compared using risk-ratio in matched cohorts. Result No significant difference in repeat EGD (5.4% vs 4.2%, RR 1.28, 0.95–1.71) or new diagnosis of gastroparesis (1.1% vs 0.6%, RR 2.00, 0.94–4.27) was noted between the groups. Conclusion GLP-1 RAs may not substantially increase the risk of repeat endoscopy in individuals without diabetes.
gastroenterology & hepatology
What problem does this paper attempt to address?